Abigail Alliance Presses For Access To Drugs With Troubled Regulatory Pasts
Executive Summary
The Abigail Alliance's legal drama with FDA has ended, but the association continues to engage the agency on a number of products it wants to see offered through expanded access programs
You may also be interested in...
FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs
FDA Rules On INDs May Embolden More Patients To Ask For Trial Drugs
Pharma firms will see few policy changes following the publication of FDA's final regulations on expanded access to investigational medicine, but the revisions could nevertheless mean more patients and doctors will come knocking on their doors asking for experimental drugs
Schering Likely To Play Up Saphris' Safety In Q4 Launch
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.